Summit-based Seqirus is ramping up its fight against influenza with the completion of a $156 million expansion of its manufacturing facility in North Carolina. The influenza-focused vaccine company ...

CSL (ASX:CSL) has outlined a restructuring plan that includes separating its Seqirus influenza vaccine business into a standalone entity. The company is also planning workforce reductions and the ...

For many businesses, "company culture" is today's trendy phrase, with little substance to back it up. At CSL Seqirus, however, a patient-focused company culture has become a guiding force from the CEO ...

CSL Seqirus, one of the world’s top flu vaccine companies, scored a $30.1 million deal from the Biomedical Advanced Research and Development Authority (BARDA) to deliver an avian flu vaccine candidate ...

Specific vaccines in the Seqirus portfolio for the upcoming flu season include Afluria Quadrivalent (ages ≥18 years), the egg-based quadrivalent influenza vaccine, and Afluria (ages ≥5 years) and ...

CSL Seqirus, a global company specialzing in the protection of public health, confirmed it is fully prepared to deliver its influenza vaccine portfolio for the 2024/25 U.S. season, based on the ...

Active seniors star in the new Seqirus commercial for Fluad, its first for the trivalent flu vaccine aimed at the 65-plus crowd. In the TV spot, older Americans say they don't have “time for ...

The Food & Drug Administration approved a multi-dose vial presentation of Audenz, a vaccine made by Summit-based Seqirus for individuals six months and older against bird flu, also known as influenza ...

The plans were announced Thursday morning as state officials approved a jobs grant worth up to $6.5 million. State and local officials are poised to announce a major economic development deal -- one ...

Seqirus Holly Springs held a ribbon cutting Monday morning to celebrate its expansion and new recognition for pandemic vaccine production and distribution. Last week, the U.S. government declared ...